Search

Cancer is the second leading cause of death globally and increasing every year, including in Indonesia. Promethium-149 (149Pm) is one of beta-emitting (Eβ-max of 1.07 MeV and T1/2 of 2.21 days) radiolanthanides that can be used for therapeutic application. Radioisotope of 149Pm can be produced with high specific activity that was suitable for labeling of biomolecule as a targeted radiopharmaceutical for cancer therapy. Radiochemical separation of 149Pm from irradiated of neodymium oxide (Nd2O3) target with 98.4% neodymium-148 (148Nd) isotope enrichment has been carried out based on extraction chromatography method using LN (Eichrom) resin column. The target material was irradiated at Bandung TRIGA 2000 reactor. Radiochemical purity the final product of 149PmCl3 radioisotope was determined using paper chromatography and paper electrophoresis methods. Radionuclide purity of 149PmCl3 solution was determined using a gamma-ray spectrometer equipped with HP-Ge detector and a multichannel analyzer (MCA). The results show that the optimum condition on separation of 149Pm from irradiated of Nd2O3 target with 98.4% 148Nd isotope enrichment was obtained using 1.5N HNO3 solution at temperature of 80 °C as mobile phase. The yield of 149Pm obtained from the separation was 97.8 ± 2.1%. The final product of 149PmCl3 radioisotope has physico-chemical characteristic that meet the requirements for nuclear medicine applications with radiochemical purity and radionuclide purity of 99.7 ± 0.2% and 99.9 ± 0.1%, respectively. The solution of 149PmCl3 was clear, with the pH of 1 and stable for 1.5 weeks at room temperature. [ABSTRACT FROM AUTHOR]